Glofitamab in the sequential treatment of relapsed/refractory B-Cell lymphoma: a single-center real-world study - Top-Institutions - MDSpire

Glofitamab in the sequential treatment of relapsed/refractory B-Cell lymphoma: a single-center real-world study

  • By

  • Haoran Xu

  • Fangce Wang

  • Chenbo Sun

  • Bing Xiu

  • Yi Ding

  • Bin Xue

  • Aibin Liang

  • Wenjun Zhang

  • July 7, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Institutional Ethics Committee of our hospital
    Institutional Ethics Committee of our hospital

    Unknown, Unknown

    Key Differentiators

    • Hematology

  • #2

    Peter MacCallum Cancer Centre
    Peter MacCallum Cancer Centre

    Melbourne, Victoria

    Key Differentiators

    • Hematology

  • #3

    The University of Melbourne
    The University of Melbourne

    Melbourne, Victoria

    Key Differentiators

    • Hematology

  • #4

    BC Cancer Centre for Lymphoid Cancer
    BC Cancer Centre for Lymphoid Cancer

    Vancouver, British Columbia

    Key Differentiators

    • Hematology

  • #5

    Charles University Hospital
    Charles University Hospital

    Prague, Prague

    Key Differentiators

    • Hematology

Original Source(s)

Glofitamab in the sequential treatment of relapsed/refractory B-Cell lymphoma: a single-center real-world study

  • by Haoran Xu, Fangce Wang, Chenbo Sun, Bing Xiu, Yi Ding, Bin Xue, Aibin Liang, Wenjun Zhang

  • July 7, 2026

Related Content

Incidence and predictors of spontaneous thyroid-stimulating hormone normalization after lobectomy for low-risk papillary thyroid microcarcinoma: evidence from contemporary clinical practice

Histopathological biomarkers of immunotherapy outcome in advanced colorectal cancer: a multicentre retrospective study

Factors associated with type 1 gastric neuroendocrine tumor occurrence in autoimmune atrophic gastritis: insights from a real-world cohort